Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on September 3, 2025
No Limits and Olivier Clovis Scaling Business Form Strategic Partnership to Support Entrepreneur Growth Across Europe
GlobeNewswire
·
September 3, 2025
Geneva, Switzerland , Sept. 03, 2025 (GLOBE NEWSWIRE) -- No Limits, the all-in-one ecosystem dedicated to entrepreneurial optimization, today announced a strategic partnership with Olivier Clovis Scaling Business, a Swiss company specializing in digital …
“Science, Art, and Service, Celebrating the 10th edition of IASC World Changers”
EIN Presswire
·
September 3, 2025
A Conversation with Prof. Dr. Gabriele Pao-Pei Andreoli ROMA, RM, ITALY, September 3, 2025 /EINPresswire.com/ -- President, Institute for Advanced Studies and Cooperation (IASC) and Lega Italiana Diritti dell’Uomo AI • Founder, World Changers Summit • …
Artelo Biosciences Announces Proposed Underwritten Public Offering
GlobeNewswire
·
September 3, 2025
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …
dLocal Announces Launch of Secondary Offering
GlobeNewswire
·
September 3, 2025
MONTEVIDEO, Uruguay, Sept. 03, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal” or the “Company”), (NASDAQ:DLO) a technology-first payments platform, today announced the commencement of an underwritten registered secondary offering of 15,000,000 Class A …
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 3, 2025
Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage …
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
GlobeNewswire
·
September 3, 2025
Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP : 23306J309), une …
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
GlobeNewswire
·
September 3, 2025
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that …
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
GlobeNewswire
·
September 3, 2025
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 …
374Water Announces Open-Market Purchases of Company Stock by Board Members and Senior Management
GlobeNewswire
·
September 3, 2025
DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) (“374Water” or the “Company”), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, today announced recent …
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire
·
September 3, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye …
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
GlobeNewswire
·
September 3, 2025
WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of …
Rail Vision Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
GlobeNewswire
·
September 3, 2025
Ra’anana, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today announced that it has received a …
Kronos Worldwide, Inc. Prices Private Offering of an Additional €75 Million of 9.50% Senior Secured Notes Due 2029
GlobeNewswire
·
September 3, 2025
Dallas, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE: KRO) (the “Company”) announced today that its wholly-owned subsidiary, Kronos International, Inc. (“KII”), has agreed to sell €75 million aggregate principal amount of …
Google Pixel Women’s Supercup 2025 | mcube™ Redefines Immersive Fan Experience in India
EIN Presswire
·
September 3, 2025
From real-time Hindi commentary to AI-powered highlights, mcube™ made global women’s football accessible and inclusive for millions in India. MUMBAI, INDIA, September 3, 2025 /EINPresswire.com/ -- The Google Pixel Women’s Supercup 2025 Final in …
Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC
GlobeNewswire
·
September 3, 2025
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement with Novatim Immune Therapeutics (Zhejiang) CO., LTD. , (“ …
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
GlobeNewswire
·
September 3, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
Longeveron® Announces Key Leadership Updates
GlobeNewswire
·
September 3, 2025
Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors Wa’el Hashad to step down as CEO and Board member …
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
GlobeNewswire
·
September 3, 2025
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte …
Asure Software Sets September 2025 Investor Conference Schedule
GlobeNewswire
·
September 3, 2025
AUSTIN, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, is scheduled to participate at the following financial conferences during …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 3, 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …